Business Overview
2021
23
$20M
Seed
2
3
Protai has built an end-to-end AI-based platform that comprehensively maps the course of disease on the protein level, enhancing the ability to observe cellular function and improve the way new drugs are discovered.
Founders (2)
| Name | Title | Contact | |
|---|---|---|---|
 | ㅤEran Seger | CEO | 1 |
 | ㅤKirill Pevzner | CTO | 1 |
Board and Advisors (2)
| Name | Title | Contact | |
|---|---|---|---|
 | ㅤTami Geiger | Advisory Board Me… | 1 |
 | ㅤAvi Ma’ayan | Advisory Board Me… | 1 |
Funding Rounds (2)
| Round | Date Announced | Investors | |
|---|---|---|---|
 | ㅤProtai raises $12 million | March 15, 2023 | 3 |
| ㅤProtai raises $8 million | January 5, 2022 | 2 |
M&A Events (0)
Investors (3)
| Investor Name | Investor Type | AUM ($) | |
|---|---|---|---|
 | ㅤGrove Ventures | Venture Capital | 335,000,000 |
 | ㅤMaj Invest | 0 | |
 | ㅤPitango Venture Capital | Venture Capital | 2,300,000,000 |
Patents (0)
Research Publications (0)
Certifications (0)
AI Technology Stack
4
Using proteomics and ML algorithms to discover better targets for diseases and develop novel drugs.
News
| Protai adds $12 million to Seed round as it aims to build oncology drug discovery pipeline |
Jobs (0)